Drugs / RBV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00996476 Background | Jul 2009 → Jan 2011 | chronic hepatitis C virus infection | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00996476 ↗ |
| Route | Oral | “300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.” NCT00996476 ↗ |